Agile Therapeutics Inc (NASDAQ:AGRX) shares were down 47.1% during mid-day trading on Friday . The company traded as low as $1.93 and last traded at $2.52. Approximately 10,342,096 shares traded hands during trading, an increase of 2,430% from the average daily volume of 408,765 shares. The stock had previously closed at $4.76.
A number of research analysts recently issued reports on AGRX shares. HC Wainwright set a $8.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Friday. ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Cantor Fitzgerald restated a “buy” rating and set a $8.00 price objective on shares of Agile Therapeutics in a research note on Monday, November 6th. Royal Bank of Canada raised their price objective on shares of Agile Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday, September 14th. Finally, Janney Montgomery Scott lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $9.80.
The stock has a market capitalization of $162.73, a P/E ratio of -2.74 and a beta of 2.03. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its holdings in Agile Therapeutics by 604.2% during the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after purchasing an additional 82,213 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Agile Therapeutics during the second quarter valued at approximately $309,000. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the second quarter worth $122,000. Caxton Corp lifted its holdings in shares of Agile Therapeutics by 12.1% in the third quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock worth $8,117,000 after buying an additional 196,445 shares in the last quarter. Finally, Pura Vida Investments LLC lifted its holdings in shares of Agile Therapeutics by 65.9% in the third quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after buying an additional 115,000 shares in the last quarter. Institutional investors own 72.92% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Agile Therapeutics (AGRX) Shares Down 47.1%” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/12/22/agile-therapeutics-agrx-shares-down-47-1.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.